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Abstract: Transplantation of stem cells, in particular mesenchymal stem cells (MSCs), stands as
a promising therapy for trauma, stroke or neurodegenerative conditions such as spinal cord or
traumatic brain injuries (SCI or TBI), ischemic stroke (IS), or Parkinson’s disease (PD). Over the last
few years, cell transplantation-based approaches have started to focus on the use of cell byproducts,
with a strong emphasis on cell secretome. Having this in mind, the present review discusses the
current state of the art of secretome-based therapy applications in different central nervous system
(CNS) pathologies. For this purpose, the following topics are discussed: (1) What are the main cell
secretome sources, composition, and associated collection techniques; (2) Possible differences of the
therapeutic potential of the protein and vesicular fraction of the secretome; and (3) Impact of the cell
secretome on CNS-related problems such as SCI, TBI, IS, and PD. With this, we aim to clarify some of
the main questions that currently exist in the field of secretome-based therapies and consequently
gain new knowledge that may help in the clinical application of secretome in CNS disorders.
Keywords: central nervous system; ischemic stroke; mesenchymal stem cells; Parkinson’s disease;
regeneration; spinal cord injury; secretome; traumatic brain injury
1. Introduction
The prevalence of people suffering from central nervous system (CNS) pathologies, such as spinal
cord injury (SCI), traumatic brain injury (TBI), ischemic stroke (IS), and Parkinson’s disease (PD),
is currently high (SCI: fluctuates between 8 per million in Spain to 83 per million in Alaska every year;
TBI: 69 million cases every year; IS: more than 2 million young adults (18–50 years) yearly; PD: varying
from 88 in Asia to 228 in South America for people aged 50–59 years) [1–4].
Although having different aetiology, symptomatology, and pathophysiology, CNS injuries and
disorders are in part challenging due to a shared feature—the low regenerative capacity of the adult
CNS [5,6]. Self and spontaneous repair of the CNS can eventually occur, although at a small scale,
through the action of endogenous neural stem cells [7]. These cells can be found in the adult CNS,
however only in specific small niches and in limited numbers, resulting in a low regenerative ability
for fully repairing damaged tissue [8].
In addition to the lower intrinsic regenerative capability of the CNS, insults to its delicate structure,
caused by trauma or injury, infections, stroke, or degeneration, often trigger several biological pathways
(e.g., cellular dysfunction or death, overactivation of immune cells, production of reactive oxygen
species or proteoglycans, and glial scar formation) that exacerbate the primary insult [9,10]. The reduced
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regeneration of neural tissue together with the development of these secondary events aggravate the
initial injury collectively, contributing to serious neurological sequels.
Currently, the clinical approach for most of the CNS disorders essentially consists in palliative care
combined with drugs (when available), which only stabilize the lesion progression. Effective treatments
to stop, reverse the neurodegenerative processes, and promote functional regeneration are lacking,
contributing to the high prevalence observed.
Candidate novel therapies have emerged in the CNS regeneration context, such as molecular
therapies [11,12], biomaterials [13], and cellular transplantation [14–16]. The last one, cell-based
therapies, have brought a particular interest to the CNS regeneration field and have been proposed
over the last decades as a possible route to repair damaged circuitries within the CNS. Several cellular
types have already been tested in a broad number of models of CNS disorders aiming to repopulate
the damaged tissue or minimize the secondary impacts of each pathology [16]. Despite their promising
results, there are still some challenges that need to be solved, namely transplantation safety, efficiency,
and mechanisms of action. Currently, a growing body of evidence points to the importance of the
paracrine signaling as a mechanism to support recovery by the transplanted cells. For instance, it has
been demonstrated that the beneficial effects observed upon mesenchymal stem cell (MSC) grafts on
the injured CNS were mainly due to secreted factors rather than cellular engraftment, in models of
spinal cord injury [14] and Parkinson’s disease [17], as reviewed elsewhere [18–20]. This new paradigm
regarding the paracrine action instead of cellular replacement or cell–cell interrelation has originated a
new possible therapeutic opportunity, using the cellular secretome to tackle diverse pathologies.
In this review, we discuss the latest advances in the secretome field and its application to
CNS disorders.
2. Cell Secretome-Based Therapy
MSC-based therapies have shown promising results for the treatment of CNS-related diseases such
as SCI [21–23], TBI [24,25], IS [26–28], and PD [20]. Although the mechanism of action remains to be
completely understood. Different studies point to the secreted factors and vesicles—their secretome—as
agents for the regenerative effect rather than cellular differentiation [14].
The term secretome was introduced by Tjalsma et al. [29], who defined it as “both the components
of machineries for protein secretion and the native secreted proteins”. This definition then evolved
to a more elaborated concept by Hathout and Agrawal in which the secretome was defined by the
factors that are secreted by a cell, tissue, or organism to the extracellular space under a defined time
and conditions [30,31]. Currently, this definition could be updated since it is known that, beyond
soluble factors, the secretome also has the presence of lipids and extracellular vesicles (EVs) carrying
important molecules [32,33].
This new concept of cell-free-based therapies focused on the cells’ secretome gained momentum
with the work of Gnecchi et al. [34]. They demonstrated that the regenerative potential of MSC
secretome in a model of heart infarct and inspired secretome application in the most diverse areas of
regenerative medicine including the CNS, as seen in Figure 1, with the emergence of publications after
2009. Moreover, as shown in Figure 1, the use of secretome has increased exponentially from 2009 until
the present day. More recently, the sole use of exosomes has also emerged as a promising therapeutic
approach, as explored in the next sections. This kind of approach overcomes many of the ethical
obstacles of cellular transplantation as well as not presenting survival or erroneous differentiation
complications of the cells in the host tissue, while preserving the potential of the paracrine action of
cellular therapy.
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Figure 1. Number of publications per year of cell-, secretome-, or exosome-based therapies on central
nervous system (CNS) disorders (Parkinson’s disease (PD), spinal cord injury (SCI), traumatic brain
injury (TBI) and ischemic stroke (IS)). An electronic research on PubMed database for literature
describing cell-, secretome-, and exosome-based therapies was performed on 18 January 2019 using
the following keywords: (cell OR cellular OR stem OR cells) AND (transplantation OR transplant OR
“Co-Transplantation” OR Cotransplantation OR engraft OR engraftment OR graft OR grafts) AND
(therapy OR therapies OR therapeutics OR therapeutic) NOT Review [Publication Type] AND (“spinal
cord injury” or “brain injury” or stroke or parkinson) AND (primates OR mice OR mouse OR rat OR
rats OR rodent OR “in vivo” OR “clinical Trials” OR humans) for cell-based therapies and (conditioned
medium OR conditioned media OR secretory OR “trophic factors” OR Exosomes OR vesicles OR
microvesicles OR vesicular OR “Extracellular vesicles” OR “nanovesicles” OR “exosomal”) AND
(therapy OR therapies OR therapeutics OR therapeutic) NOT Review[Publication Type] AND (“spinal
cord injury” or “brain injury” or stroke or parkinson) AND (primates OR mice OR mouse OR rat
OR rats OR rodent OR “in vivo” OR “clinical Trials” OR humans) for secretome- and exosome-based
therapies. The search retrieved 3676 articles for cell-based therapies and 682 articles for secretome- and
exosome-based therapies. Data extraction was independently performed by two researchers.
Given the potential of secretome application to CNS disorders, several advances in this field
have recently been made. The following sections discuss some of the major achievements in this new
field, with a focus on secretome production, standardization, optimization of the collecting protocols,
and its composition.
3. Collecting Procedure
Generally, the procedure to obtain secretome from any cellular type follows the same guidelines.
Briefly, after a cell culture is established, the growing media (typically supplemented with exogenous
factors) is removed and the cells are washed and incubated 24 h to 48 h in a serum-free media with
antibiotic (conditioned period). After the conditioned period, only the factors released by the cells
(secretome/conditioned media (CM)) are collected and stored at −80◦C after being snap-frozen to
maintain its biological properties [17,35,36]. In the last decade, new conditioning methodologies have
been used to prime the cells to produce different pools of molecules, as detailed below. Methodologies
can take advantage of hypoxia, cell activation with apoptotic stimuli, inflammatory stimulus, or even
the use of bioreactors.
Hypoxia. In regular conditions, cellular cultures are maintained at 5% of relative CO2 and
21% O2. However, under oxygen deprivation, the MSCs alter their secretome properties, enhancing
the production of chemoattractant factors (interleukin-8 (IL-8), monocyte chemoattractant protein-1
(MCP-1), RANTES, granulocyte-macrophage colony-stimulating factor (GM-CSF) and angiogenic
mediators (angiogenin, matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor-A
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(VEGF-A), VEGF-C and elevating inflammatory modulators (IL-1b, IL-6, IL1-15, IL-1Ra) [37–39].
This alteration on preconditioned cells is also reported to be related to increases on secretome
therapeutic potential. In non-CNS-related pathologies, secretome preconditioned in hypoxia from
adipose stem cells (ASCs) is reported to improve recovery in a model of hepatic injury in both
in vitro and in vivo, with upper regulation of enzymes with antioxidant properties [40]. In other
injury scenarios, this preconditioning method of MSCs seems to potentiate the wound healing and
regenerative process provided by the secretome [41–43] when delivering the total secretome or only the
vesicular fraction [44,45]. In pathologies related to the CNS, using the secretome of cells preconditioned
by hypoxia in a rat model of TBI led to a significantly better performance both in motor and cognitive
tests together with minor brain damage when compared with normoxic-secretome [46].
Inflammatory stimuli. Other methods to modulate the secretome profile of the cells are carried
out using inflammatory cytokines; in this case the preconditioning usually results in modulation of the
immunoregulatory proteins. Regarding stimulation with tumor necrosis factor alpha (TNF-α), Lee et al.
showed an increase of IL-8 and IL-6 when compared with un-preconditioned secretome of ASCs [47].
Actually, the same findings were corroborated later by Heo et al., who also observed beneficial effects
on wound healing, angiogenesis, and immune cell infiltration due to those cytokines [48]. Furthermore,
TNF-α seems to be a potent inducer of VEGF production in MSCs [49,50]. Even though the mechanism
of secretome modulation remains unknown, more works have been performed in this field. It is also
known that lipopolysaccharide preconditioning of ASCs increases the levels of the immunomodulators
TNF-α and IL-6 as well as increasing the regenerative profile [51] of secretome.
Molecular stimulation. Preconditioning the cells with other molecular stimuli also seems to
modulate the secretome composition. As in the case of hydrogen peroxide (H2O2), when it is provided
to ASCs in culture, their secretome shows a better capability to promote cytoprotective and pro-recovery
effects on fibroblasts under oxidative stress when compared to ASCs in regular culture [52]. In a case
of skin flap, only the exosome fraction was used and it was observed that pre-stimulation with H2O2
promoted survival and angiogenesis while reducing inflammation when compared with normal ASC
secretome [53]. Due to these secretory properties, ASCs stimulated with H2O2 are currently being
employed in a clinical trial with patients with spinal cord injury (NCT02917291).
Additional molecular methods have been used to modulate the secretome profile such as the
pre-activation of cells with signals to stimulate the sonic hedgehog (SHH) pathway; in this case,
Wharton’s jelly (WJ)-derived mesenchymal stem cell secretome improved their angiogenic potential
when compared with control [54]. The use of drugs, as in the case of trimetazidine and diazoxide,
also seems to play a role in human embryonic-derived mesenchymal stem cell secretome when
preconditioned with a drug; this primed secretome promotes the increase of immunomodulatory
molecules by peripheral blood mononuclear cells (PBMCs) such as IL-10, TNF-α, and IL-1β [55].
Improvements in the secretome of ASCs was also observed increasing the secretion of pro-angiogenic,
neuroprotective, and anti-inflammatory molecules and increasing the antioxidant capacity of their
secretome when preconditioned with deferoxamine [56]. Another innovative approach is to use cellular
extracts including cues of the traumatic tissue and to stimulate the cells with the extracts prior to use
in vivo on the correspondent disease. In a case of TBI, the traumatic injury-preconditioned secretome
increased the differentiation, migration, and maturation of new-born cells, improving the cognitive
function after the trauma [57]. In summary, the previous approaches to preconditioning the secretome
indicate the immeasurable alternatives available to obtain personalized secretome according to each
objective and to target the most varied aspects of CNS pathologies.
Bioreactors. MSC secretome is currently a promising source to treat CNS pathologies in models of
injury and disease, as briefly mentioned before and explored in the following sections. Therefore, one
challenge of secretome collection is the step from small-scale production to a bigger scale. While the
conventional methods (e.g., culture flasks) work perfectly for small applications, this is not feasible for
clinical applications. Currently, the secretome of MSCs is obtained from adherent flask cultures, which is
very labor intensive. Furthermore, due to the high number of flasks needed, the risk of variability
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between flasks, as well as possible contaminations during the process, increases significantly [58].
Therefore, different authors have suggested the use of bioreactors to produce secretome. These dynamic
culturing systems allow the biological processes to occur under controlled conditions: temperature, pH,
medium flow rate, oxygen supply, and control of nutrient and metabolite exchanges [58,59]. Moreover,
they allow the expansion to a high number of cells in one vessel with consequent higher secretome
production compared with traditional systems [60]. Despite these positive aspects, the bioreactor
systems provide a different environment and external stimuli to the cells compared to the adherent
flask culture, producing differences in the secretome profile as already reported, which as a last resort
could be suitable. Teixeira et al. demonstrated that human bone marrow (hBM)-MSCs expanded
in bioreactors improve differentiation of human neural progenitor cells (hNPCs) to neurons when
compared with secretome from static cultures in vitro [61]. Additionally, the use of bioreactors improves
the neuroregulatory properties of the secretome of those cells, inducing a higher number of NPCs to
differentiate into neurons, increasing the number of dopaminergic neurons and improving the motor
performance of PD rat models [17].
The basic insights provided in this section suggest that cell secretome could be modulated
depending on the external cues provided. As such, future research may focus on developing secretome
targeted to different needs, enriching secretome in specific biofactors depending on the pathophysiology
of the injury and/or disease under study.
In conclusion, despite the therapeutic value associated with secretome in CNS regenerative
diseases as described in the following sections, the production methods remain to be standardized and
still face some problems when comparing different studies. These problems include the production
protocol, use of different concentrations, and differences in the secretome composition. As such, these
problems introduce some concern when comparing results between distinct publications. In order
to fill those gaps, methods to characterize the secretome composition are already available as is the
case of non-target proteomic analysis, which allows researchers to have a wide detection ability and
potentially detect any protein present in the secretome [62]. This step is crucial to standardizing
techniques and simplifying knowledge to make advances in the secretome field.
4. Secretome Composition
MSCs can be obtained from different sources including bone marrow (BM-MSCs), adipose tissue
(ASCs), and umbilical cord tissue (Wharton’s jelly mesenchymal stem cells (WJ-MSCs) and human
umbilical cord perivascular cells (HUCPVCs), just to highlight the most commonly cited.
Similarly to what has been reported for BM-MSCs, growth factors such as vascular endothelial
growth factor (VEGF), glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor
(BDNF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), nerve growth factor (NGF),
insulin-like growth factors 1 and 2 (IGF-1 and IGF-2), transforming growth factor beta 1 (TGF- β1),
and others have also been found in ASC secretome [62,63] being able to increase neuronal and glial
viability [64] (Figure 2). In more detail, VEGF is a mitogen-activated protein that participates in
the formation of new blood vessels and in cellular processes, such as proliferation, growth, and
survival. Importantly, on the nervous system, VEGF could be associated with neurogenesis [65,66],
neuromaturation [67], neuroprotection [68,69], and even neuroregeneration [70]. This effect occurs
through VEGF receptor and MAPK/Erk1/2 signal transduction pathways which are mediating the
growth effects on CNS neurons [68]. As such, VEGF fosters the reorganization of the spinal motor
network after SCI [71] and also underlies a protective effect against ischemia [69]. Among currently
known neurotrophic factors, GDNF has the most pronounced neuroprotective effect, which is
particularly relevant in ischemic brain damage [72,73] and neurodegenerative diseases [74–76].
The effects of GDNF on GluR2-containing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors reduce the postsynaptic membrane permeability to calcium ions, which may be
considered a possible mechanism for protecting neural cells from hypoxic damage [73]. This mechanism
of GDNF in the maintenance of the main parameters of Ca2+ activity also has a protective effect on
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the neuron–glia networks and their functional structure [77]. Additionally, by binding to their main
receptor (GRFα), GDNF activates several intracellular signaling cascades such as Ras/MAPK and
PI3K/Akt, which can suppress pro-apoptotic proteins (p53) and caspases (caspase 3 and 9), promoting
neural survival [78]. FGF is a multi-functional growth factor which includes a potent angiogenic
potential and plays important roles in the differentiation and function of CNS cells. Importantly, FGF is
crucial during CNS development and therefore it may also play an essential role in neurodegenerative
disorders [79]. Indeed, the possible manipulation of FGF2/FGFR1 offers therapeutic opportunities for
Alzheimer’s [80] and Parkinson’s diseases [81].
Moreover, Salgado and coworkers [82] pointed out that the secretome from WJ-MSCs and
HUCPVCs is also able to increase survival, proliferation, and differentiation of hippocampal neurons
due to the presence of, for example, NGF and FGF [82,83]. Additionally, the BDNF present on these cell
secretomes is mediating axonal growth [84]. Figure 2 highlights ASC secretome composition, referring
to specific biofactors and their biologic effect on the nervous system.
Figure 2. Mesenchymal stem cell secretome composition and their main effects on the CNS. On their
soluble fraction (red circles), MSC secretome contains cytokines, chemokines, growth factors, and
glycoproteins. On their vesicular fractions (orange circles), the exosomes and microvesicles contain
essentially microRNAs. Both the soluble and the vesicular fractions may act on distinct damaged cells of
the nervous system, promoting their survival, angiogenesis, neurite outgrowth, and immunomodulation.
This information is based on the articles [85,86].
The cell secretome comprises a myriad of biocomponents and can be divided into two distinct
fractions—the soluble fraction (essentially proteins and soluble factors such as cytokines) and
the vesicular fraction. Indeed, it is known that the secretome from the different MSC sources
contains a soluble fraction rich in pro- and anti-inflammatory cytokines, extracellular matrix proteins,
neuroprotective and neurodifferentiation agents, or even neurite growth factors [37,87], as briefly
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mentioned above. On the other hand, they also present a vesicular fraction, composed of exosomes,
microvesicles, and apoptotic bodies [88]. These vesicles containing nucleic acids (e.g., messenger
RNAs and microRNAs) and small proteins are secreted through membranal fusion to the extracellular
space [89,90]. With this mechanism they are able to modulate the activity of target cells by interacting
directly with the cell membrane through an antibody receptor or releasing their biologic content on
cell cytoplasm, finally inducing angiogenesis [91,92] and neurite outgrowth [93,94] and regulating
inflammatory responses [95,96]. From 2013 onward, research on the use of exosome (nano-scaled
vesicles with sizes ranging from 30 to 120 nm)-based therapies has been increasing, as shown also
in Figure 1. Exosomes are drawing the attention of the regenerative medicine field because of their
therapeutic potential for CNS regeneration [97,98]. Nevertheless, this field is still in its infancy, and as
such, more extensive studies are still needed to fully understand the therapeutic potential of these
vesicular structures.
Significant knowledge regarding secretome and its constituents has been accumulated over the
past few years. However, there are still questions that need to be addressed. It is important to
validate and further dissect the individual contribution of either the protein or vesicular fractions of
the secretome as compared to the effects that were observed using the total secretome. For instance,
are the traditional cytokines and growth factors the main mediators of the paracrine actions promoted
by stem cell secretome? Or, instead, are the extracellular vesicles sufficient by acting as transporters of
the therapeutic cargo? The answers to these and other questions are now being explored since they are
important to the further design of CNS regenerative strategies.
5. Secretome Fractions: Where Is the Therapeutic Potential?
Although the cell secretome is now being considered for regenerative medicine, one frequent and
important aspect considered about this therapy is its mechanism of action. In this sense, different
fractions of the secretome are being thoroughly characterized and analyzed by its immunomodulation
and regenerative and/or protective potential. Another important aspect is the possible interaction
between different molecules present in the secretome that may act synergistically to potentiate the
therapeutic effect. An interesting way of studying the contribution of different fractions to the
therapeutic value of the secretome is to separate the soluble factors from the EVs.
As mentioned previously, several authors have already reported the presence of many proteins
in the secretome that have a positive effect on neuronal survival, differentiation, neurite outgrowth,
and immunomodulation. Indeed, factors such as GDNF, NGF, HGF, VEGF, IGF-1 and 2, chemokine
(C-X-C motif) ligand (CXCL 16), IL-6 and 10, TGF β1, and MCP-1 have been related to the neuro- and
immunoregulatory character of MSC secretome [63,87,99,100]. Thus, when applied to CNS disorders,
these soluble factors could improve the therapeutic outcomes, as is explored in the next section.
This revealed the potential of a single or a group of cytokines and growth factors, acting in coordinated
mode to potentiate tissue repair.
However, the vesicular fraction by itself could also constitute a powerful therapeutic approach
since EVs are similarly involved in intercellular communication and may contain all the signals required
for a successful contact [101]. Increasing evidence shows that cells modify the EV content in response to
the microenvironment, revealing that EVs are involved not only in intracellular signaling but also in the
global mechanism of maintaining physiological homeostasis [90]. Therefore, EVs carry nucleic acid and
proteins in their lumen or in their lipid membrane to mediate intercellular communication [102,103].
Thus, proteins could also act by the fusion of EVs with recipient cells, allowing the target delivery
of soluble factors while maintaining their stability and biological potency as it keeps them protected
from microenvironment proteases. Moreover, nucleic acids such as mRNAs, microRNAs, and tRNAs
present in EVs may potentially target factors involved in stem cell self-renewal and immune-related
mechanisms [104]. The small size of EVs compared to whole cells also offers therapeutic benefits,
including easier injection, reduced macrophage phagocytosis, and improved extravasation through
the injured site [105]. Some studies have also shown that EVs offer innate biocompatibility, high
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physical-chemical stability, cell selective fusion, and long-distance communication [106–108]. The cargo
transference between different cells allows a rapid alteration in gene expression and control of
critical processes and cell functions [109]. Additionally, EVs could be chemically and biologically
modified to broaden, alter, and/or enhance their therapeutic capability [103,105,110], the engineering
of EVs becoming an emerging focus of research. The therapeutic potential of EVs has received the
attention of researchers in the field of CNS pathologies such as SCI [53,84,111,112], IS [113–115], and
PD [92,116–118]. Indeed, the administration of MSC-derived exosomes could restore tissue function in
multiple disease/injury models [97].
Besides the facts mentioned above, the mediators of the secretome therapeutic potential still
need to be further clarified. In that context, the impact of each part—soluble and vesicular—should
be evaluated in order to understand their individual value, as well as to understand the secretome
therapeutic potential for each disorder context, specifying their action to specific dysfunctional
mechanisms present on the pathology. The next section explores the therapeutic opportunities offered
by the MSC secretome to several neuro disorders, in the context of trauma or neurodegeneration.
In each case, the interaction between molecules and vesicles or solely the MSCs’ trophic factors/vesicles
could be presented as the mediators of the secretome’s mechanism of action.
6. Secretome Applications to CNS Disorders
The cell secretome is an essential component of both the paracrine and autocrine cell signaling
mechanism, having therefore an important role in the regulation of many physiological processes.
Additionally, several molecules are present in its constitution that help in neuronal tissue repair either
by acting directly on neurons to protect them from further damage and promoting regeneration or by
indirectly by mechanisms such as immunomodulation. Its effects on neuronal survival, regeneration,
and/or immunomodulation through the action of soluble and vesicular factors are crucial for reducing
or even stopping disease progression and for promoting repair [33]. Consequently, there is increasing
interest in their study to help understand different pathologies and identify potential therapeutic targets.
In this section, we analyze the current applications of stem cell secretome as a new tool for the
treatment of CNS diseases, focusing for this purpose on MSC secretome, as it is currently the primary
source for these applications. Thus, the secretome from the different MSC sources has shown to be
a valid tool for the neuroprotection and survival of neuronal and glial cells through the release of a
range of multiple trophic factors and vesicles.
6.1. Spinal Cord Injury (SCI)
SCI leads to long-term functional deficits due to the loss of neurons and glial cells, inflammation,
and demyelination [18]. The occurrence of the lesion creates a non-permissive inflammatory and
chemical environment for neuronal regeneration. The release of immune modulatory and neurotrophic
paracrine factors into the lesion site by MSCs could modulate that environment to promote glial scar
reduction, immunomodulation, axonal regeneration, and neurite outgrowth. Indeed, the effect of cell
transplantation has been proven to be due to the trophic factors as BDNF, HGF, and NGF [119–122]
which were able to promote axonal growth and vascularization after SCI. At the in vitro level, MSC-CM
also plays a primary role in skewing pro-inflammatory M1 microglia stimulated with lipopolysaccharide
(LPS) toward inflammation-resolving M2 cells [123]. More specifically, secretome from ASCs reduced
the production of TNF-α by M1 macrophages while enhancing TGF β1 and IL-10 release by M2
macrophages [124]. in vivo, injecting BM-MSC secretome into the lesion site is reported to promote
neuroprotection, leading to reduction of the cystic cavity and preservation of the spinal tracts, leading
overall to locomotor recovery of SCI animals [125,126]. Related to the administration solely of the
vesicular fraction, MSC exosomes could promote pro-angiogenic and anti-inflammatory effects and
axonal regeneration, and suppress glial scar formation and cell apoptosis, attenuating the lesion
size and improving functional recovery after traumatic SCI [127–129]. Additionally, an intravenous
injection of MSCs or MSC-derived exosomes in an SCI context revealed a comparable therapeutic
Pharmaceuticals 2020, 13, 31 9 of 18
effect [130]. Overall, these findings suggest an interaction between soluble molecules and vesicles
secreted by MSCs with neuronal and immune cells, reinforcing the prospective clinical value of using
the secretome or the vesicles released by these cells on SCI treatment.
6.2. Traumatic Brain Injury (TBI)
TBI is characterized by external mechanical forces causing brain injury, which potentially cause
physical, cognitive, and emotional impairments to the patients [131,132]. Due to the immunomodulatory
properties of MSCs, their secretome may also be used to modulate the secondary injury mechanisms
of TBI, controlling the exaggerated inflammatory response, reducing pro-inflammatory cytokines,
and promoting an increase in neural stem cell proliferation and differentiation [133–135]. Several factors
secreted by MSCs such as NGF, GDNF, BDNF, and Wnt3a could attenuate the loss of cholinergic
neurons in the medial septum of mice and still promote hippocampal neurogenesis [136,137].
Furthermore, extracellular vesicles secreted by MSCs have been shown to reduce neuroinflammation
and promote neurogenesis and angiogenesis, rescuing spatial learning and motor impairments in TBI
animal models [138–143]. These effects could be mediated by the miRNA content of those vesicles,
which already have been demonstrated to be able to regulate, for example, neurite outgrowth by
the transfer of miR-133b to neural cells [90]. These studies may indicate the potential value of MSC
secretome as a potential therapy for TBI.
6.3. Ischemic Stroke (IS)
IS is a cerebrovascular disease that results from blood vessel occlusion or damage, leading to the
suppression of blood supply and therefore resulting in focal tissue loss and death of endothelial and
neuronal cells [132]. The application of MSC secretome in this context revealed also that the factors
released by these cells such as IGF-α and BDNF could promote neuroprotection, by blocking neuronal
damage and tissue loss [144]. Moreover, the MSCs’ paracrine factors inhibit the activation of p38
MAPK and JNK, which attenuate astrocyte injury by GFAP downregulation. Additionally, Chopp’s lab
added evidence about the MSC exosomes’ therapeutic potential, demonstrating that the administration
of BM-MSC exosomes 24 h after injury resulted in increased neurogenesis and angiogenesis in the
ischemic boundary zone [145]. Indeed, the administration of MSC extracellular vesicles led to post
ischemic immunosuppression, providing a successful environment for brain remodeling [146–148].
6.4. Parkinson’s Disease (PD)
PD is a neurodegenerative disorder characterized by the progressive degeneration of dopaminergic
neurons. As a result, patients develop motor complications such as rigidity, bradykinesia, and postural
instability [20]. In PD, cell replacement therapies could be an attractive strategy for replacing the
progressive loss of nigral dopaminergic neurons. However, the injection of MSC secretome has
already shown to induce beneficial effects, promoting a partial reversion of the PD histological
deficits and gains on animals’ motor performance [17]. This could be achieved by the secretion of
neurogenic, neurodevelopmental, neurorescuing, or anti-apoptotic factors or, in another point of view,
by immunomodulatory and anti-inflammatory mediators present on the MSC secretome. Additionally,
Mendes-Pinheiro et al. have shown that, in fact, secretome-based therapies could be more efficient
than their cell transplant counterparts, in a similar model of PD [149]. Particularly interesting were
the results reported by Hee et al. showing that the secretome from MSCs can reduce the α-synuclein
aggregates, one of the hallmarks of the disease, through an MMP-2-based mechanism [150].
Based on the cited studies, it is clear that there is increasing evidence that stem cell secretome
can have neuroprotective, neuroregenerative, and immunomodulatory actions. Many studies support
the conclusion that the recovery of neural and glial function in CNS trauma and disorders is due to
the secretion of soluble factors and vesicles by the transplanted MSCs rather than by cell replacement.
A study using MSC transplantation in an SCI model also supported this observation as no MSCs were
found within the host tissue, but an increase in factors such as NGF could instead be observed [120].
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These secreted bioactive products can suppress local inflammation, enhance angiogenesis, inhibit
apoptosis, and stimulate proliferation and differentiation of tissue-resident cells. Although most of
the described approaches still remain at experimental stages, continuing efforts in developing new
secretome-based therapies for CNS disorders will enable the adoption of these techniques into a
clinical context.
7. Conclusions
Central nervous system dysfunction, caused by either injury or disease, leads to a disruption of
the complex network between neuronal and glial cells, having a profound effect on a patient’s life.
The restricted regenerative capacity of the adult CNS and the following inhibitory environment make
the innate repair process extremely limited. To tackle this limitation, several therapeutic approaches
have been tested including pharmacological or cellular therapies. The latter is a promising strategy,
although several difficulties related to ethical and safety concerns, tissue availability, and graft rejection
concerns must be overcome. As we have reviewed here, a recent paradigm shift has emerged suggesting
that these cells might exert beneficial effects through their paracrine effects—the secretome—rather
than by cellular replacement. Thus, while early studies primarily attributed the beneficial effects
underlying stem cell therapy to its differentiation and replacement competence, it is now known that the
therapeutic action is strongly mediated through paracrine factors that include soluble factors and EVs,
which (as we pointed out here) apparently provide a supportive environment to host damaged CNS
cells and enhance endogenous regenerative processes following injury or disease, promoting significant
improvements when compared to vehicle treatments. Furthermore, secretome derivates may represent
a considerable advantage over cells when considering manufacturing, storage, and long product shelf
life. However, this still presents some obstacles to increasing the robustness of the approach.
Here, we presented the current knowledge regarding production methods used to improve the
secretion of certain molecules and the use of bioreactors to scale up the process and standardize the
collection methods, to obtain large amounts of secretome. Nevertheless, understanding the mechanism
behind the shift in the molecular constitution still remains, and the methods needed to scale up secretome
collection must still be widely implemented to decrease the demand on manual processes and increase
good manufacturing practices that follow good quality standards. Another interesting aspect to help
comprehend and optimize secretome application to CNS disorders is a deeper understanding of the
secretome composition, and how each part is interacting with different pathologies. This represents an
important step forward and will help understand secretome interaction with different pathologies
in a global perspective. As a long shot, the combination of these aspects of the knowledge about the
secretome may allow the development of targeted secretome to tackle different pathophysiological
deficits in a multidisciplinary way. Nonetheless, secretome as therapy also has limitations concerning
especially tissue transport, protein stability, and half-life time. This reinforces the need to develop new
delivery strategies. Therefore, some options are currently appearing, such as the coupling of secretome
with bioengineered materials to extend the duration of secretome therapeutic effects. Biomaterials are
often used since they mimic the native extracellular matrix but also provide structural support to the
transplanted factors. A combinatory approach could enhance the positive effects, such as the coupling
of biomaterials, cells, and biological factors, which promote accelerated tissue repair. In this review,
we showed that the development of secretome-based therapies for CNS disorders is an interesting but
still emerging field, with positive results in both smaller mammals and in vitro, dissecting priming
methods to modulate the secretome profile, unveiling the secretome composition, and elucidating
the different secretome fractions. Those aspects must be further explored so that secretome and its
components can be validated as a valuable therapy for CNS disorders.
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